<DOC>
	<DOCNO>NCT02435654</DOCNO>
	<brief_summary>In study , investigator recruit 100 DSM-Ⅴdefined EOS Han patient , old 7 year old onset illness 17 year old , EOS patient receive 8-week systematic olanzepine titration treatment battery assessment treatment effect safety . Blood olanzepine plasma concentration test regularly genotyping 8 polymorphisms 5-HTR2A , DRD2 COMT gene conduct Polymerase Chain Reaction （PCR） , Restriction Fragment Length Polymorphism ( RFLP ) TaqMan probe genotyping technology . The aim study explore predictive factor olanzepine treatment response EOS , guide individualize treatment improve cure rate EOS clinical setting .</brief_summary>
	<brief_title>5-HTR2A , DRD2 , COMT Genes Polymorphisms Olanzapine Plasma Concentration Treatment Early-onset Schizophrenia</brief_title>
	<detailed_description>Early-onset schizophrenia ( EOS ) World Health Organization rank psychosis third disable condition worldwide youth , may lead obvious social dysfunction interfere seriously neurodevelopmental process young person , turn potential irreversibly alter trajectory life . To improve outcome patient EOS , elaborate individualize therapeutic regimen urgently need . The functional gene polymorphism drug ( antipsychotic ) plasma concentration influence drug response , study explore contribution genetic heterogeneity , drug plasma concentration clinical feature patient drug response together interaction factor EOS patient . In study investigator recruit 100 DSM-Ⅴdefined EOS Han patient , old 7 year old onset illness 17 year old , EOS patient receive 8-week systematic olanzepine titration treatment battery assessment treatment effect safety . Blood olanzepine plasma concentration test regularly genotyping 8 polymorphisms 5-HTR2A , DRD2 COMT gene conduct Polymerase Chain Reaction （PCR） , Restriction Fragment Length Polymorphism ( RFLP ) TaqMan probe genotyping technology . The aim study explore predictive factor olanzepine treatment response EOS , guide individualize treatment improve cure rate EOS clinical setting .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>7 year old , age onset ≤17 year old , Han nationality , male female , line diagnostic DSMV criterion schizophrenia , negative positive symptom scale ( Positive Negative Syndrome Scale , PANSS ) score ≥70 point ; patient condition firstepisode , relapse . IQ &lt; 70 , current previous history traumatic brain injury , psychoactive substance use , personality disorder , obvious abnormality physical laboratory examination , previous allergy olanzapine significant adverse reaction .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Genes Polymorphisms</keyword>
	<keyword>Plasma Concentration</keyword>
</DOC>